The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Celltrion's (KRX:068270) biosimilars Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and Avtozma (tocilizumab), Celltrion said Monday.
Eydenzelt, comparable to Eylea, targets retinal disorders such as wet AMD and diabetic macular edema. Stoboclo and Osenvelt are at par with Prolia and Xgeva for osteoporosis and cancer-related conditions. Avtozma is comparable to RoActemra for rheumatoid arthritis and other inflammatory diseases, the press release said.
The products require European Commission approval for marketing in the European Union.
Shares of Celltrion rose more than 1% in recent trade on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。